SLV-154 Treatment of Advanced Cancers

Part of paid clinical trials in Newport Beach, California.

Sponsor
Solve Therapeutics
Study ID
NCT06771219
Phase
PHASE1
Status
Recruiting

Conditions

  • Advanced Cancer
  • Advanced Solid Tumor
  • Metastatic Cancer

Eligibility Criteria

Sex
ALL
Age
12 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • SLV-154 — DRUG
    SLV-154

Study Details

This is a Phase 1 study comprising a Phase 1a dose-escalation portion and a Phase 1b expansion portion evaluating the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of SLV-154 across a range of dose levels when administered to subjects with advanced solid tumors.

Key Dates

First listed
Jan 13, 2025
Start date
May 14, 2025
Status verified
Jul 2026
Primary completion
Aug 31, 2027
Completion
Nov 30, 2027

Study Design

Enrollment
250 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Dose Level 1
    0.75 mg/kg
  • Experimental: Dose Level 2
    1.5 mg/kg
  • Experimental: Dose Level 3
    3.0 mg/kg
  • Experimental: Dose Level 4
    4.0 mg/kg
  • Experimental: Dose Level 5
    5.0 mg/kg
  • Experimental: Dose Level 6
    6.5 mg/kg

Primary Outcome Measure

Phase 1a: MTD and/or RDR [ Time Frame: Through the duration of treatment, up to approximately 18 months ]

Central Contacts

Locations (10)

FacilityCityStateZIPSite coordinators
Hoag Memorial Hospital PresbyterianNewport BeachCalifornia92663
Cindy Do, BSN, RN
949-764-4624
Washington UniversitySt LouisMissouri63110
Sara Mitchum
3142738602
Astera Cancer CareEast BrunswickNew Jersey08816
Percy Yeung
732-387-3378
Memorial Sloan Kettering Cancer CenterNew YorkNew York10065
Roisin O'Cearbhaill, MD
646-888-4227
University Hospitals Cleveland Medical CenterClevelandOhio44106
Afshin Dowlati, MD
212-844-6031
MD Anderson Cancer CenterHoustonTexas77030
Rabia Khan
713-563-4667
Oncology ConsultantsHoustonTexas77030
Julio Peguero, MD
713-600-0900
Mays Cancer Center; University of Texas Health San AntonioSan AntonioTexas78229
Daruka Mahadevan, MD
210-450-1000
Daruka Mahadevan (PRINCIPAL_INVESTIGATOR)
University of Washington / Fred Hutchinson Cancer CenterSeattleWashington98109
Phase 1 Clinical Trials
206-606-7551
Northwest Medical Specialties, PLLCTacomaWashington98405
CarrieAnn Brown
253-428-8700
Kiersten Peart
253-428-8700

Find similar trials in Newport Beach, CA

Related Studies